For the quarter ending 2026-03-31, RYTM made $60,112K in revenue. -$56,743K in net income. Net profit margin of -94.40%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 60,112 | 57,253 | 51,298 | 48,502 |
| Cost of sales | 7,157 | 4,802 | 5,499 | 5,543 |
| Research and development | 41,725 | 42,032 | 46,027 | 42,308 |
| Selling, general, and administrative | 63,591 | 57,482 | 52,425 | 45,947 |
| Total costs and expenses | 112,473 | 104,316 | 103,951 | 93,798 |
| Loss from operations | -52,361 | -47,063 | -52,653 | -45,296 |
| Other income (expense), net | -1,704 | 58 | 274 | 1,576 |
| Gain on settlement of forward contract | - | 0 | - | - |
| Interest expense | 4,583 | 4,615 | 4,742 | 5,817 |
| Interest income | 3,554 | 4,084 | 4,328 | 3,242 |
| Total other income (expense), net | -2,733 | -473 | -140 | -999 |
| Loss before income taxes | -55,094 | -47,536 | -52,793 | -46,295 |
| Provision for income taxes | 545 | -31 | 111 | 337 |
| Net loss | -55,639 | -47,505 | -52,904 | -46,632 |
| Accrued dividends on convertible preferred stock | 1,104 | 1,332 | 1,375 | 1,349 |
| Net loss | -56,743 | -48,837 | -54,279 | -47,981 |
| Foreign currency translation adjustment | - | -883* | - | - |
| Unrealized (loss) gain, net on marketable securities, net of tax | - | 126* | - | - |
| Comprehensive loss | - | -49,594 | - | - |
| Basic EPS | -0.83 | -0.741 | -0.82 | -0.75 |
| Diluted EPS | -0.83 | -0.741 | -0.82 | -0.75 |
| Basic Average Shares | 67,974,193 | 66,932,865 | 66,261,055 | 63,684,359 |
| Diluted Average Shares | 67,974,193 | 66,932,865 | 66,261,055 | 63,684,359 |
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)